Terbinafine Hydrochloride

DRUG5 trials

Sponsors

Novartis, NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.), Nitric BioTherapeutics, Inc, South End Skin Care

Conditions

Candidiasis, OralHIV InfectionsOnychomycosisOnychomycosis/Onycholysis and Tinea PedisTinea CapitisTinea Pedis

Phase 1

Safety and Pharmacokinetics of Terbinafine Hydrogen Chloride (HCl) Nail Lacquer in Patients With Onychomycosis

CompletedNCT00691184

NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)Onychomycosis/Onycholysis and Tinea Pedis

Start: 2005-02-28End: 2005-12-31Updated: 2008-06-05

Phase 2

Efficacy and Safety Study of Iontophoretic Application of Terbinafine Gel in Subjects With Onychomycosis

CompletedNCT01080079

Nitric BioTherapeutics, IncOnychomycosis

Start: 2010-05-31End: 2012-06-30Updated: 2012-10-19

Three-Arm Trial of Novel Treatment for Tinea Pedis

CompletedNCT03135912

South End Skin CareTinea Pedis

Start: 2017-01-03End: 2017-08-02Updated: 2017-10-06

Phase 3

Terbinafine Compared to Griseofulvin in Children With Tinea Capitis

CompletedNCT00117754

NovartisTinea Capitis

Start: 2004-07-31End: 2006-04-30Target: 720Updated: 2007-02-21

Unknown Phase

Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment

CompletedNCT00002394

NovartisCandidiasis, Oral, HIV Infections

Target: 30Updated: 2005-06-24